Private company

Tercica

А defunct biopharmaceutical company

Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1).3 From Wikipedia, CC BY-SA 4.0

Last updated Oct 18, 2026.

Overview

  • Industryhealth care1
  • HeadquartersDE1
  • Incorporated inDE4
  • Business address2000 Sierra Point Parkway, Suite 400, Brisbane, Ca 940054

See how the biggest companies compare on our leaderboards

Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.3

Leadership

Who has led Tercica, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John A. Scarlett2006–2008

Chief financial officer

  1. Susan Wong2006
  2. Ajay Bansal2006–2008
2010201520202025
Board members and other officers (18)

Timeline

  1. Mar 14, 2006New chief executive John A. Scarlett becomes CEO5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23